Sparrow Pharmaceuticals Expands Executive Leadership With Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality
Retrieved on:
Tuesday, August 17, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Industry, South Manila Inter-Institutional Consortium, Regulatory affairs, Drug development, Therapy, Metabolism, Tissue, Macpherson, Doctor of Philosophy, Endocrine Society, American Association, National, Autoimmunity, Repligen, Steroid, Medication, Â, Patient, Toxic leukoencephalopathy, Doctor of Pharmacy, Association, Merck Serono, MD, Pharmaceutical industry
Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the appointment of Frank Czerwiec, MD, PhD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality.
Key Points:
- Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the appointment of Frank Czerwiec, MD, PhD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality.
- He maintains an active medical license and is a member of the Endocrine Society and American Association of Clinical Endocrinologists.
- The addition of Frank and Jamie to our leadership team significantly strengthens our capabilities as a clinical development organization, said Robert Jacks, President and Chief Executive Officer of Sparrow.
- As Vice President of Regulatory Affairs and Quality, Dr. MacPherson will lead interactions with regulatory authorities worldwide and oversee the implementation of Sparrows quality management systems.